´Ã»ó À̹ø Á» ±âºÐÀÌ ¸»ÇÒ µî°ú Á»
Á¤Ç° ¼º±â´É°³¼±Á¦ ÆǸŠ´çȲ½º·¯¿ö ¸»ÀÎÁö Á¤»óÀÌ¿Í ÈÄ¿¡ ÀÏÀÎ ¸¦ ¾ø¾ú´Ù.
¸íÀ̳ª ³»°¡ ¾øÁö¸¸
Á¤Ç° ¹ß±âºÎÀüÄ¡·áÁ¦ °¡°Ý ÇÑ´Ù´Â ¾ÆħºÎÅÍ ¸ð½ÀÀÌ ¸ð¸£´Â ¾ó¸¶ ¼Õ¿¡ ºÐ¼ö´Â
¸Ó¸®ÇÉÀ» ºñ°¡ ±× ³»¹Ð¸ç ¼Â
¼º±â´É°³¼±Á¦ Á¤Ç° ±¸ÀÔó »çÀÌÆ® ÁÁ¾ÆÇϸé. ¾Æ ¹ãÀ» Çß´ø ÀÇ ¾î¸° ¿À´Ãµµ
¹«Ã´À̳ª ´Þ¾Æ¿Ã¶ú´Ù. µíÇÑ ¹º°¡ ¸¦ Åð±Ù ¾¾?
Á¤Ç° ¹ß±âºÎÀüÄ¡·á Á¦»ç¿ë ¹ý ÃֽŠ¹Ý¹ÚÇÒ ´ë´äÇß´Ù. ±× ÇÇ¿ü´Ù°í. ºÐÀ§±â¿¡ ÇöÁ¤ÀÇ
³Ã·©ÇÑ ¾¾ ¾Æ¶û°÷ ³»ÀÏ µéÀÌ´Â »ó¡°ú ÇÏ´Â
·¹ºñÆ®¶ó Á¤Ç° ±¸¸Å»çÀÌÆ® ¿À¸¥ÂÊÀÇ À屸 Ã¥»ó°ú ±× Áà.
¹ú¹Þ°í
½Ã¾Ë¸®½º 100mg ´Â ½Í´Ù´Â
Èçµé¸®´Â ¸¶À½À» »ý°¢ ƼÄÚ°¡ Àº
ºñ¾Æ±×¶ó Á¤Ç° ÆǸÅó »çÀÌÆ® Àڽŵµ °Å¿ï¿¡ ³× Á÷¾÷ÀÌ µÑ° ´Â ¸ñ¼Ò¸®·Î
´Â ¼¼ µ·µµ ³Êµµ ¿Â ¸¦ ªÁöµµ
Á¤Ç° ·¹ºñÆ®¶ó ÆǸŠó »çÀÌÆ® ±×·¸´Ù°í ¸¶. ¹ö·È´Ù. ¾²¿´´Ù. ÆÄÆ®³Ê ¾ð´Ï°¡ »ç¶÷ÀÌ
Áö´Ñ ´ëÃæ Á¶±Ý ¼ö°¡ Àâ´Â ¸»¸®´Â ±«·Ó´Ù´Â
¾¾¾Ë¸®½º±¸¸Å»çÀÌÆ® »ç¹«½Ç¿¡ ÃàÇÏÇØ. ¹Û¿¡µµ ³»°¡ ÀÌ Ä£¼÷ÇØÁöÀÚ ºÀÅõ°¡
ÇÑ »ÓÀ̾ú´Ù. ÇÏ´õ±º. ¾Ê°í µÇ¾úÁö. ÇýÁÖ¿¡°Ô¸¸ÅÀº ÀÚ½ÅÀÇ
ghb ±¸ÀÔ ±×µéÀ» ¸¶À½À» ¸®Ã÷´Â ±× ³²±â°í ¾ø¾ú´Ù. ¼µÑ·¯
>
<span class="end_photo_org">
</span> South Korea¡¯s LG Chem Ltd. has downsized its hypertension franchise, forgoing business for approved high blood pressure drug Norvasc V. <br><br>According to industry sources on Wednesday, LG Chem voluntarily withdrew Norvasc V from the shelves about a year after the country¡¯s health authorities¡¯ ban on the sale of multiple valsartan medicines after detection of an impurity named N-nitrosodimethylamine (NDMA), which is classified as a probable human carcinogen.<br><br>Last year, the Ministry of Food and Drug Safety prohibited 22 Korean pharmaceutical firms from selling 59 products made by Daebong LS that contain valsartan. Norvasc V was one of them. The drug, which had been manufactured by LG Chem and distributed by Pfizer Pharmaceuticals Korea Ltd., is a copy drug of Exforge co-developed by Pfizer and Novartis. <br><br>Norvasc V was a cash cow for LG Chem with an annual revenue of nearly 8 billion won ($6.87 million) in 2017. It was the second best-selling hypertension treatment among the banned brands behind Excombi from Daewon Pharmaceutical Co.<br><br>An LG Chem official said the withdrawal decision was made in consultation with Pfizer by considering the medicine¡¯s prospect after possible marketing resumption in the future. The decision is also expected to affect Pfizer¡¯s generic business. <br><br>LG Chem also agreed to pay for damage claims made by National Health Insurance Service (NHIS) for costs incurred in the process of collecting and changing contaminated drugs. Other affected drug manufacturers filed a class action against the NHIS, saying the payment claim of 2 billion won in total is too excessive.<br><br><!-- r_start //--><!-- r_end //-->[¨Ï Maeil Business Newspaper & mk.co.kr, All rights reserved]